These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 17060265)

  • 21. Effectiveness of botulinum toxin B in the treatment of drooling.
    George KS; Kiani H; Witherow H
    Br J Oral Maxillofac Surg; 2013 Dec; 51(8):783-5. PubMed ID: 23962595
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A double-blind, placebo-controlled, randomized, crossover pilot study of the safety and efficacy of multiple doses of intra-oral tropicamide films for the short-term relief of sialorrhea symptoms in Parkinson's disease patients.
    Lloret SP; Nano G; Carrosella A; Gamzu E; Merello M
    J Neurol Sci; 2011 Nov; 310(1-2):248-50. PubMed ID: 21636098
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of sialorrhea in children with cerebral palsy: a double-blind placebo controlled trial.
    Alrefai AH; Aburahma SK; Khader YS
    Clin Neurol Neurosurg; 2009 Jan; 111(1):79-82. PubMed ID: 18977585
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and efficacy of botulinum toxin type B for treatment of sialorrhea in Parkinson's disease: a prospective double-blind trial.
    Chinnapongse R; Gullo K; Nemeth P; Zhang Y; Griggs L
    Mov Disord; 2012 Feb; 27(2):219-26. PubMed ID: 21887710
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potential problems surrounding the use of sublingually administered ophthalmic atropine for sialorrhea.
    Leung JG; Schak KM
    Schizophr Res; 2017 Jul; 185():202-203. PubMed ID: 28043733
    [No Abstract]   [Full Text] [Related]  

  • 26. Sublingual administration of atropine eye drops for treating sialorrhea after stroke: A randomized controlled trial.
    Wang L; Li A; Zhang C; Ding X; Xu H
    J Stroke Cerebrovasc Dis; 2024 Oct; 33(12):108050. PubMed ID: 39366591
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical effects of adjunctive atropine during ketamine sedation in pediatric emergency patients.
    Kye YC; Rhee JE; Kim K; Kim T; Jo YH; Jeong JH; Lee JH
    Am J Emerg Med; 2012 Nov; 30(9):1981-5. PubMed ID: 22748697
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of Sublingual Atropine Drops in Clozapine-Associated Sialorrhea in an Adolescent Patient: A Case Report.
    Akça D; Güneş A; Karaçetin G
    J Clin Psychopharmacol; 2022 Nov-Dec 01; 42(6):606-607. PubMed ID: 36251377
    [No Abstract]   [Full Text] [Related]  

  • 29. Nonsurgical treatment of drooling in a patient with closed head injury and severe dysarthria.
    Dworkin JP; Nadal JC
    Dysphagia; 1991; 6(1):40-9. PubMed ID: 1884637
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term incobotulinumtoxinA treatment for chronic sialorrhea: Efficacy and safety over 64 weeks.
    Jost WH; Friedman A; Michel O; Oehlwein C; Slawek J; Bogucki A; Ochudlo S; Banach M; Pagan F; Flatau-Baqué B; Dorsch U; Csikós J; Blitzer A
    Parkinsonism Relat Disord; 2020 Jan; 70():23-30. PubMed ID: 31794936
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Effect of Glycopyrrolate on Nocturnal Sialorrhea in Patients Using Clozapine: A Randomized, Crossover, Double-Blind, Placebo-Controlled Trial.
    Man WH; Colen-de Koning JC; Schulte PF; Cahn W; van Haelst IM; Doodeman HJ; Egberts TC; Heerdink ER; Wilting I
    J Clin Psychopharmacol; 2017 Apr; 37(2):155-161. PubMed ID: 28129312
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transdermal scopolamine for reduction of drooling in developmentally delayed children.
    Lewis DW; Fontana C; Mehallick LK; Everett Y
    Dev Med Child Neurol; 1994 Jun; 36(6):484-6. PubMed ID: 7516297
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transdermal buprenorphine in the treatment of chronic pain: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study.
    Sorge J; Sittl R
    Clin Ther; 2004 Nov; 26(11):1808-20. PubMed ID: 15639693
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism.
    Mancini F; Zangaglia R; Cristina S; Sommaruga MG; Martignoni E; Nappi G; Pacchetti C
    Mov Disord; 2003 Jun; 18(6):685-8. PubMed ID: 12784273
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [What to do in neuroleptic-induced sialorrhea].
    Fischer RB
    Psychiatr Prax; 2001 Jul; 28(5):249-50. PubMed ID: 11517914
    [No Abstract]   [Full Text] [Related]  

  • 36. Efficacy, safety, and tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain: a randomized, double-blind, placebo-controlled study.
    Hashemi M; Zali A; Golmakani E; Delshad MH; Shadnoush M; Akbari ME
    Daru; 2021 Jun; 29(1):51-59. PubMed ID: 33475984
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Botulinum toxin A versus B in sialorrhea: a prospective, randomized, double-blind, crossover pilot study in patients with amyotrophic lateral sclerosis or Parkinson's disease.
    Guidubaldi A; Fasano A; Ialongo T; Piano C; Pompili M; Mascianà R; Siciliani L; Sabatelli M; Bentivoglio AR
    Mov Disord; 2011 Feb; 26(2):313-9. PubMed ID: 21259343
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Submandibular gland botulinum neurotoxin A injection for predicting the outcome of submandibular duct relocation in drooling: a retrospective cohort study.
    Kok SE; van Valenberg HFJP; van Hulst K; Jongerius P; Erasmus CE; van den Hoogen FJA
    Dev Med Child Neurol; 2019 Nov; 61(11):1323-1328. PubMed ID: 30854648
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Botulinum toxin type A for drooling in Parkinson's disease: a double-blind, randomized, placebo-controlled study.
    Lagalla G; Millevolte M; Capecci M; Provinciali L; Ceravolo MG
    Mov Disord; 2006 May; 21(5):704-7. PubMed ID: 16440332
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low-Concentration Atropine for Myopia Progression (LAMP) Study: A Randomized, Double-Blinded, Placebo-Controlled Trial of 0.05%, 0.025%, and 0.01% Atropine Eye Drops in Myopia Control.
    Yam JC; Jiang Y; Tang SM; Law AKP; Chan JJ; Wong E; Ko ST; Young AL; Tham CC; Chen LJ; Pang CP
    Ophthalmology; 2019 Jan; 126(1):113-124. PubMed ID: 30514630
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.